CN105327110A - Medicine for treating allergic rhinitis - Google Patents
Medicine for treating allergic rhinitis Download PDFInfo
- Publication number
- CN105327110A CN105327110A CN201510776536.7A CN201510776536A CN105327110A CN 105327110 A CN105327110 A CN 105327110A CN 201510776536 A CN201510776536 A CN 201510776536A CN 105327110 A CN105327110 A CN 105327110A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- allergic rhinitis
- treatment
- rhizoma atractylodis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 26
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 229940079593 drugs Drugs 0.000 title abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 3
- 210000004072 Lung Anatomy 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 210000003734 Kidney Anatomy 0.000 abstract description 4
- 210000000952 Spleen Anatomy 0.000 abstract description 4
- 241000668709 Dipterocarpus costatus Species 0.000 abstract description 2
- 240000005389 Glycyrrhiza glabra Species 0.000 abstract 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 2
- 241000234435 Lilium Species 0.000 abstract 2
- 240000001313 Lycium barbarum Species 0.000 abstract 2
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 2
- 235000015468 Lycium chinense Nutrition 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 2
- 235000014063 licorice root Nutrition 0.000 abstract 2
- 235000011477 liquorice Nutrition 0.000 abstract 2
- 238000002474 experimental method Methods 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 238000010792 warming Methods 0.000 abstract 1
- 206010028748 Nasal obstruction Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 210000001331 Nose Anatomy 0.000 description 7
- 206010039101 Rhinorrhoea Diseases 0.000 description 7
- 210000002850 Nasal Mucosa Anatomy 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000003203 everyday Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 230000001058 adult Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 230000001932 seasonal Effects 0.000 description 3
- 210000003097 Mucus Anatomy 0.000 description 2
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 description 2
- 206010048908 Seasonal allergy Diseases 0.000 description 2
- 230000002009 allergen Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940005497 ANTICHOLINERGIC AGENTS Drugs 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N Chromone Chemical class C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010050515 Hyposmia Diseases 0.000 description 1
- 229940080780 Loratadine 10 MG Drugs 0.000 description 1
- 210000003928 Nasal Cavity Anatomy 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033775 Paraesthesia Diseases 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 206010039095 Rhinitis seasonal Diseases 0.000 description 1
- 206010041232 Sneezing Diseases 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 230000002052 anaphylactic Effects 0.000 description 1
- 230000002590 anti-leukotriene Effects 0.000 description 1
- 230000002146 bilateral Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000019559 hyposmia Nutrition 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000001314 paroxysmal Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention relates to medicine for treating allergic rhinitis. The medicine is prepared from, by weight, 10 parts of rhizoma atractylodis macrocephalae, 9 parts of liquorice, 15 parts of barbary wolfberry fruit, 9 parts of lilies, 8 parts of radix ophiopogonis, 3 parts of folium nelumbinis and 8 parts of herba asari. According to the medicine, rhizoma atractylodis macrocephalae and liquorice can strengthen the spleen and benefit Qi, barbary wolfberry fruit can nourish the kidney and moisten the lung, lilies and radix ophiopogonis can moisten the lung and clear away the heart fire, folium nelumbinis can send up the lucid Yang, and herba asari can dispel cold and open the orifices. All the traditional Chinese medicines are combined to jointly achieve the effects of tonifying the lung, strengthening the spleen, opening the orifices through pungent warming to effectively treat the allergic rhinitis. Clinical experiments prove that the medicine can safely and effectively treat the allergic rhinitis.
Description
Technical field
The present invention relates to a kind of Chinese medicine, be specifically related to a kind of medicine being used for the treatment of allergic rhinitis.
Background technology
Allergic rhinitis and allergic rhinitis, after referring to atopic individuals contact allergen, primarily of medium (mainly histamine) release of IgE mediation, and have the nasal mucosa non-infectious inflammatory disease that panimmunity competent cell and cytokine etc. participate in.
Classical symptom mainly paroxysmal sneeze, clear water sample nasal mucus, nasal obstruction and the rhinocnesmus of allergic rhinitis.Part is with hyposmia.
1. sneeze
For several times paroxysmal outbreak every day, at every turn more than 3, how morning rise or night or contact allergy former after show effect at once.
2. thin nasal discharge
A large amount of clear water sample nasal mucus, can not consciously drip from nostril sometimes.
3. have a stuffy nose
Interval or lasting, one-sided or bilateral, light and heavy degree differs.
4. rhinocnesmus
Most patients intranasal is itched, and pollinosis patient can accompany ophthalmic pruritus, itching in the ear and itching throat.
Diagnosis: more than 2 (containing 2) appear in the symptoms such as clinical symptoms sneeze, clear water sample tears, nasal obstruction, nose are overworked, every day Symptoms last or be accumulated at more than 1 hour.Can with the eye symptom such as ophthalmic pruritus, conjunctival congestion.The common nasal mucosa of sign is pale, edema, nasal cavity watery secretion.Skin prick test is positive, and/or Specificity IgE is positive, feasible nasal provocation test if desired.
Drug therapy
Following factor should be considered: curative effect, safety, expense/effect ratio etc.Conventional intranasal and oral administration, curative effect may be variant between different patient.Without long-term sustained therapeutic effect after drug withdrawal, therefore maintaining treatment is needed to persistence allergic rhinitis.There is not quick drug resistance in the extended treatment time.Intranasal administration has many advantages, and high concentration medicine can directly act on nose, avoid or reduces systemic side effects.But for other anaphylactic diseases patient, medicine needs act on different target organ, and intranasal administration is not optimum selection, recommend systemic drug treatment.Pregnant Patients should be cautious use of various medicine.
(1) the oral or nose 2nd generation of antihistaminic or novel H1 antihistaminic, can effectively alleviate the symptoms such as rhinocnesmus, sneeze and watery nasal discharge.Be applicable to mild intermittent and mild consistent allergic rhinitis, in treating by glucocorticosteroidsin in combination with nose-severe allergic rhinitis.
(2) glucocorticoid nose glucocorticoid, can effectively alleviate the symptoms such as nasal obstruction, watery nasal discharge and sneeze.To the reactionless patient with severe symptoms that maybe can not tolerate nasal medicine of other drug treatment, oral glucocorticoid can be adopted to carry out short term therapy.
(3) anti-leukotriene medicine to allergic rhinitis and asthma effective.
(4) chromone class medicine has certain effect to alleviation sniffle, and eye drop is effective to alleviation eye symptom.
(5) intranasal Decongestant has mitigation to the nasal obstruction symptom that nasal congestion causes, and the course for the treatment of should control within 7 days.
(6) Intranasal anticholinergic agents thing effectively can suppress watery nasal discharge.
Medical material involved in the present invention is recorded in all as seen " China's book on Chinese herbal medicine ".
Summary of the invention
The present invention aims to provide a kind of medicine being used for the treatment of allergic rhinitis, by selecting suitable medical material and proportioning thereof, reaches the object of safe and effective healing allergic rhinitis.
In order to achieve the above object, the present invention is by the following technical solutions:
Be used for the treatment of a medicine for allergic rhinitis, it is characterized in that, it is prepared from by the raw medicinal material of following weight proportion: the Rhizoma Atractylodis Macrocephalae 10 parts, 9 parts, Radix Glycyrrhizae, Fructus Lycii 15 parts, Bulbus Lilii 9 parts, Radix Ophiopogonis 8 parts, 3 parts, Folium Nelumbinis, Herba Asari 8 parts.
Below in conjunction with theories of Chinese materia medica, beneficial effect of the present invention is described:
Inventor thinks, primary disease is mainly due to lung qi virtual loss, and instability of surface, wind and cold is availed oneself of the opportunity to get in, and violate and nose key, pathogen conflicting with vital QI, lung qi must not lead to tune, and body fluid stops gathering, and nose key is jammed, and then causes sneeze, snivel.Enriching of lung qi, depend on the defeated cloth of temper, and the root of gas is at kidney, suffers from a deficiency of the kidney, and takes the photograph to receive to have no right, gas does not return unit to cause primary disease.
The present invention uses: the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae invigorating the spleen and benefiting QI; Fructus Lycii nourishing kidney lung moistening; Bulbus Lilii, lung moistening Radix Ophiopogonis clear away heart-fire; Folium Nelumbinis sending up the lucid YANG; Herba Asari cold expelling is sensible.All medicines share, and play tonifying the lung spleen invigorating altogether, effect that Xin Wen is sensible.Effective treatment of allergic rhinitis.
Below in conjunction with clinical laboratory data, beneficial effect of the present invention is described:
1, physical data
Inventor collects 80 routine Allergic Rhinitis between in June ,-2014 in June, 2012 altogether, wherein man 31 example, female 49 example, and perennial onset 34 example, Seasonal Incidence 46 example, the age is 18 ~ 72 years old, the course of disease 1 ~ 18 year.Treatment group and each 40 examples of matched group are divided at random by medical sequencing.Treatment group man 12 example, female 28 example; Perennial onset 18 example, Seasonal Incidence 22 example; 32 ~ 70 years old age, average (52.0 ± 9.4) year; The course of disease 1 ~ 18 year.Matched group man 19 example, female 21 example; Perennial onset 16 example, Seasonal Incidence 24 example; 32 ~ 70 years old age, average (51.1 ± 11.4) year; The course of disease 1 ~ 17 year.The data there was no significant differences such as two groups of sexes, age, courses of disease, have comparability.
Diagnostic criteria
(1) there is rhinocnesmus, sneeze, nasal discharge and nasal obstruction 4 large symptoms at least 3, more than Symptoms last 0.5-1h, weekly more than 4d; Seasonal rhinitis or pollinosis, annual morbidity season is basically identical, and be consistent with pollen pollinating period (within least 2 years, falling ill in same season).Perennial rhinitis was then fallen ill in most date in 1 year; (2) nasal mucosa form inflammatory changes; (3) the former tuerculoderma of degeneration is positive, and at least one is that more than (++) or (++)/or allergen specific lee are positive; (4) nasal smear eosinophilic granulocyte checks the positive paresthesia epilepsy phase.Mainly can make diagnosis according to first 3, wherein medical history and specificity inspection be Main Diagnosis according to.
2, Therapeutic Method
The capsule that the oral the present invention for the treatment of group obtains according to embodiment 3, every day 3 times.Treat 1 month.
The oral loratadine 10mg of matched group, every day 1 time.Treat 1 month.
3, criterion of therapeutical effect and therapeutic outcome
3.1 criterion of therapeutical effect
Observe sneeze before and after treatment, snivel, nasal obstruction, the improvement situation of the symptoms such as rhinocnesmus, all cases all adopt treatment cross-reference method.Recovery from illness: transference cure, toposcopy is shown in that nasal mucosa is normal, without recurrence in 1 year; Effective: rhinorrhea with clear discharge disappears, even sneeze, nasal obstruction, rhinocnesmus is alleviated; Take a turn for the better: sneeze reduces, and snivel alleviates, nasal obstruction, rhinocnesmus improves; Invalid: symptom is without improvement.
3.2 treatment statistical results are in table 1.
Table 1 liang group comparitive study
Visible, the medicine that the present invention obtains can safe and effective treatment of allergic rhinitis, and cure rate is high.
Detailed description of the invention
In order to understand better and implement the present invention, further illustrate the present invention below in conjunction with specific embodiment.
Embodiment 1
Take: the Rhizoma Atractylodis Macrocephalae 10 grams, 9 grams, Radix Glycyrrhizae, Fructus Lycii 15 grams, Bulbus Lilii 9 grams, Radix Ophiopogonis 8 grams, 3 grams, Folium Nelumbinis, Herba Asari 8 grams; Add 8 times of water gagings, decoct 1.5 hours, filter; Filtering residue adds 6 times of water gagings, decocts 1 hour, filters; Merging filtrate, is concentrated into 120 grams, must meet the decoct of adult normal's one day consumption.
Be used for the treatment of allergic rhinitis.Oral, daily once.
Embodiment 2
Take: the Rhizoma Atractylodis Macrocephalae 10 grams, 9 grams, Radix Glycyrrhizae, Fructus Lycii 15 grams, Bulbus Lilii 9 grams, Radix Ophiopogonis 8 grams, 3 grams, Folium Nelumbinis, Herba Asari 8 grams; Add 10 times of water gagings, decoct 2 hours, filter; Filtering residue adds 8 times of water gagings, decocts 1.5 hours, filters; Merging filtrate, concentrated, dry, packaging, must meet the powder of adult normal's one day consumption.
Be used for the treatment of allergic rhinitis.Oral, every bu is taken for twice sooner or later.
Embodiment 3
Take: the Rhizoma Atractylodis Macrocephalae 10 grams, 9 grams, Radix Glycyrrhizae, Fructus Lycii 15 grams, Bulbus Lilii 9 grams, Radix Ophiopogonis 8 grams, 3 grams, Folium Nelumbinis, Herba Asari 8 grams; Add 6 times of water gagings, decoct 3 times, each decoction 1 hour, merges decoction liquor, concentrated, dry, incapsulates shell, must meet the capsule of adult normal's one day consumption.
Be used for the treatment of allergic rhinitis.Oral, every bu morning, noon and afternoon take for three times.
Claims (4)
1. be used for the treatment of a medicine for allergic rhinitis, it is characterized in that, it is prepared from by the raw medicinal material of following weight proportion: the Rhizoma Atractylodis Macrocephalae 10 parts, 9 parts, Radix Glycyrrhizae, Fructus Lycii 15 parts, Bulbus Lilii 9 parts, Radix Ophiopogonis 8 parts, 3 parts, Folium Nelumbinis, Herba Asari 8 parts.
2. a kind of medicine being used for the treatment of allergic rhinitis as claimed in claim 1, it is characterized in that, its preparation method is: take: the Rhizoma Atractylodis Macrocephalae 10 parts, 9 parts, Radix Glycyrrhizae, Fructus Lycii 15 parts, Bulbus Lilii 9 parts, Radix Ophiopogonis 8 parts, 3 parts, Folium Nelumbinis, Herba Asari 8 parts; Add 8 times of water gagings, decoct 1.5 hours, filter; Filtering residue adds 6 times of water gagings, decocts 1 hour, filters; Merging filtrate, is concentrated into 120 parts, obtains decoct; Above-mentioned part all refers to weight portion.
3. a kind of medicine being used for the treatment of allergic rhinitis as claimed in claim 1, it is characterized in that, its preparation method is: take: the Rhizoma Atractylodis Macrocephalae 10 parts, 9 parts, Radix Glycyrrhizae, Fructus Lycii 15 parts, Bulbus Lilii 9 parts, Radix Ophiopogonis 8 parts, 3 parts, Folium Nelumbinis, Herba Asari 8 parts; Add 10 times of water gagings, decoct 2 hours, filter; Filtering residue adds 8 times of water gagings, decocts 1.5 hours, filters; Merging filtrate, concentrated, dry, packaging, obtains powder; Above-mentioned part all refers to weight portion.
4. a kind of medicine being used for the treatment of allergic rhinitis as claimed in claim 1, it is characterized in that, its preparation method is: take: the Rhizoma Atractylodis Macrocephalae 10 parts, 9 parts, Radix Glycyrrhizae, Fructus Lycii 15 parts, Bulbus Lilii 9 parts, Radix Ophiopogonis 8 parts, 3 parts, Folium Nelumbinis, Herba Asari 8 parts; Add 6 times of water gagings, decoct 3 times, each decoction 1 hour, merges decoction liquor, concentrated, dry, incapsulates shell, obtains capsule; Above-mentioned part all refers to weight portion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510776536.7A CN105327110A (en) | 2015-11-10 | 2015-11-10 | Medicine for treating allergic rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510776536.7A CN105327110A (en) | 2015-11-10 | 2015-11-10 | Medicine for treating allergic rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105327110A true CN105327110A (en) | 2016-02-17 |
Family
ID=55278016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510776536.7A Pending CN105327110A (en) | 2015-11-10 | 2015-11-10 | Medicine for treating allergic rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105327110A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101134095A (en) * | 2006-08-29 | 2008-03-05 | 肖祖胜 | Traditional Chinese medicine composition for treating allergic rhinitis |
| CN101698000A (en) * | 2009-10-23 | 2010-04-28 | 张晓波 | Traditional Chinese medicine for treating allergic rhinitis |
| CN103736072A (en) * | 2014-01-28 | 2014-04-23 | 张怀胜 | Medicament for treating allergic rhinitis and preparation method of medicament |
| CN104840817A (en) * | 2015-05-18 | 2015-08-19 | 西宁科进工业设计有限公司 | Traditional Chinese medicine for treating allergic rhinitis |
-
2015
- 2015-11-10 CN CN201510776536.7A patent/CN105327110A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101134095A (en) * | 2006-08-29 | 2008-03-05 | 肖祖胜 | Traditional Chinese medicine composition for treating allergic rhinitis |
| CN101698000A (en) * | 2009-10-23 | 2010-04-28 | 张晓波 | Traditional Chinese medicine for treating allergic rhinitis |
| CN103736072A (en) * | 2014-01-28 | 2014-04-23 | 张怀胜 | Medicament for treating allergic rhinitis and preparation method of medicament |
| CN104840817A (en) * | 2015-05-18 | 2015-08-19 | 西宁科进工业设计有限公司 | Traditional Chinese medicine for treating allergic rhinitis |
Non-Patent Citations (2)
| Title |
|---|
| 吴朝晖: ""蔡氏抗敏鼻炎方治疗过敏性鼻炎35例"", 《安徽中医临床杂志》 * |
| 谢水祥等: ""变应性鼻炎的病因病机及辨证论治"", 《时珍国医国药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872425B (en) | Traditional Chinese medicine decoction for treating climacteric syndrome | |
| CN101700336B (en) | Chinese herba preparation for curing craniocerebra trauma residual headache and preparation method | |
| CN106334077A (en) | Traditional Chinese medicine prescription for treating allergic rhinitis | |
| CN102772650B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof | |
| CN102526459B (en) | Traditional Chinese medicine composition for treating nasosinusitis and preparation method thereof | |
| CN101884779A (en) | Siberian solomonseal rhizome composition for intervening sub-health state and preparation method thereof | |
| CN103432222A (en) | Medicine for treating allergic rhinitis | |
| CN101757408A (en) | Medicament for treating lupus erythematosus and preparation method thereof | |
| CN101869653B (en) | Chinese medicinal preparation for treating chronic nasosinusitis and preparation method thereof | |
| CN103356906B (en) | Traditional Chinese medicine preparation for caring insomniac and preparation method | |
| CN105327110A (en) | Medicine for treating allergic rhinitis | |
| CN101716326B (en) | Medicament for treating children chronic cough and allergic rhinitis and preparation method thereof | |
| CN101406685A (en) | Medicament for treating bronchial asthma and preparation method thereof | |
| CN109420115A (en) | A kind of Chinese medicinal formulae for female climacteric syndrome conditioning | |
| CN103417886A (en) | Traditional Chinese medicine composition for treating bronchial asthma and preparing method thereof | |
| CN102526368B (en) | Traditional Chinese medicine composition for treating nasosinusitis and preparation method thereof | |
| CN103007023A (en) | External traditional Chinese medicine composition for treating cough variant asthma of adult | |
| CN103028046A (en) | Traditional Chinese medicine composition for treating atrophic rhinitis and preparation method of traditional Chinese medicine composition | |
| CN102626503B (en) | Chinese medicinal oral liquid for smoothing heart and enhancing intelligence | |
| CN111569003B (en) | Traditional Chinese medicine composition for treating cough variant asthma and extract and application thereof | |
| CN102552423B (en) | Medicinal composition for treating migraine | |
| CN107441317A (en) | It is a kind of to be used for the special Chinese medicinal formulae for reporting the treatment of constitution allergic rhinitis | |
| CN104857414A (en) | Medicine composite for treating chronic simple rhinitis | |
| CN105362548A (en) | Traditional Chinese medicine for treating allergic asthma | |
| CN104587297A (en) | Traditional Chinese medicine capsule for treating scleroderma and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160217 |
|
| WD01 | Invention patent application deemed withdrawn after publication |